Entia Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Sherwood, Oregon. The company went IPO on 2007-11-01. The firm also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The firm's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The firm's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.
How did ERGO's recent EPS compare to expectations?
The most recent EPS for Entia Biosciences Inc is $, expectations of $.
How did Entia Biosciences Inc ERGO's revenue perform in the last quarter?
Entia Biosciences Inc revenue for the last quarter is $
What is the revenue estimate for Entia Biosciences Inc?
According to of Wall street analyst, the revenue estimate of Entia Biosciences Inc range from $ to $
What's the earning quality score for Entia Biosciences Inc?
Entia Biosciences Inc has a earning quality score of B/40.14765. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Entia Biosciences Inc report earnings?
Entia Biosciences Inc next earnings report is expected in
What are Entia Biosciences Inc's expected earnings?
Entia Biosciences Inc expected earnings is $, according to wall-street analysts.
Did Entia Biosciences Inc beat earnings expectations?
Entia Biosciences Inc recent earnings of $ expectations.